Accessibility Menu
Zealand Pharma A/s logo

Zealand Pharma A/s(OTC) ZLDPF

Market Cap$3.28BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2012)+277%
5 Year+70%
1 Year-32%
1 Month-0%
$47.64
+0.72%
+0.34Today
Zealand Pharma A/s last closing stock price
MetricPriceDate
Last closeUSD 47.302026-09-02
Zealand Pharma A/s stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-8.7%USD 51.812026-08-25
1 month-0.42%USD 47.502026-08-03
3 month-3.51%USD 49.022026-06-04
Year to date-33.94%USD 71.602025-12-31
1 year-31.94%USD 69.502025-09-02
3 year+26.81%USD 37.302023-08-31
5 year+69.84%USD 27.852021-08-25
Since inception+276.89%USD 12.552012-02-14

Zealand Pharma A/s Financials at a Glance

Market Cap

$3.28BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

DKK 4.63B

Net Income (TTM)

DKK 2.73B

EPS (TTM)

$6.00

P/E Ratio

7.82

Dividend

$0.00

Beta (Volatility)

0.38 (Low)

Price

$47.64

Volume

2,035

Open

$47.73

Previous Close

$47.64

Daily Range

$47.64 - $47.73

52-Week Range

$35.93 - $83.12

Estimated Earnings Date

Nov 12, 2026

ZLDPF News

Person Computer 5.jpg

A Weight-Loss Rival Just Crashed 23%. Why That's Great News for Eli Lilly and Novo Nordisk.

Bram BerkowitzJun 8, 2026
3 investors gather around a laptop

2 Weight Loss Stocks That Are Screaming Buys in December

Alex CarchidiDec 15, 2024
researcher works at lab bench

GLP-1 Stocks Aren't the Only Way to Benefit From the Weight Loss Drugs Boom

Alex CarchidiOct 13, 2024
two investors put sticky notes on glass wall

This GLP-1 Biotech Stock Could Give Novo Nordisk a Run for Its Money

Alex CarchidiAug 25, 2024
doctors with investors

This Rising Biotech Is a Fantastic Weight-Loss Stock to Buy Now

Alex CarchidiAug 21, 2024
Investor at home looking at multiple charts.

Missed Out on Eli Lilly? This Much Smaller Biotech Has 2 Promising Weight Loss Assets in its Portfolio

David Jagielski, CPAJul 5, 2024
A team of scientists reviewing results in a lab.

Missed Out on Novo Nordisk? This Much Smaller Danish Biotech Could Be the Next Hot Weight-Loss Stock.

David Jagielski, CPAMar 14, 2024

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Zealand Pharma A/s

Zealand Pharma A/S is a biotechnology company based in Copenhagen, Denmark, focused on the entire lifecycle of peptide-based medicines. The company specializes in developing treatments for gastrointestinal and metabolic disorders, as well as other specialized conditions.

Products and Services
  • Adlyxin and Lyxumia, targeting diabetes management
  • Dasiglucagon, for severe hypoglycemia and congenital hyperinsulinism
  • Pipeline candidates including glepaglutide for short bowel syndrome
Growth Outlook
  • Dasiglucagon is advancing through Phase III trials for congenital hyperinsulinism
  • Glepaglutide is also in Phase III trials, indicating strong pipeline potential
  • Strategic collaborations with major pharmaceutical companies enhance growth opportunities
Financial Highlights
  • Recent quarterly revenue of 4.47 billion DKK shows significant growth
  • Net income for Q2 2026 reached 3.90 billion DKK, reflecting strong profitability
  • Cash and short-term investments total approximately 14.4 billion DKK, indicating solid liquidity
Zealand Pharma A/S operates in a dynamic sector with a focus on innovative peptide-based therapies. The company's current products, such as Adlyxin and Dasiglucagon, address critical health issues, while its robust pipeline promises future growth. Recent financial performance highlights a strong revenue increase and profitability, positioning the company favorably within the biotechnology industry. With strategic partnerships and ongoing clinical trials, Zealand Pharma is well-positioned to capitalize on emerging opportunities in the healthcare market.
AI Generated • Aug 26, 2026

Industry

Biotechnology

Sector

Health Care

Employees

578

CEO

Adam Sinding Steensberg, MD, MBA

Website

www.zealandpharma.com

Headquarters

Søborg, 2860, DK

ZLDPF Financials

Key Financial Metrics (TTM)

Gross Margin

99.22%

Operating Margin

50.57%

Net Income Margin

59.00%

Return on Equity

17.54%

Return on Capital

46.96%

Return on Assets

13.86%

Earnings Yield

12.79%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.28BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

69.39M

Volume

2.04K

Avg. Volume

779.656

Financials (TTM)

Gross Profit

DKK 4.60B

Operating Income

DKK 2.33B

EBITDA

DKK 2.47B

Operating Cash Flow

-DKK 1.38B

Capital Expenditure

-DKK 40.34M

Free Cash Flow

-DKK 1.42B

Cash & ST Invst.

DKK 14.41B

Total Debt

DKK 409.54M

Zealand Pharma A/s Performance Analysis

Zealand Pharma A/s annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31DKK 14,690,202-14.8%
20232023-12-31DKK 49,737,397238.6%
20242024-12-31DKK 9,091,613-81.7%
20252025-12-31DKK 1,393,445,09915226.7%
Zealand Pharma A/s sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-99.5%
Q42025-12-3138.7%
Q12026-03-31-50.5%
Q22026-06-3013048.2%
Zealand Pharma A/s annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31DKK -2.955.5%
20232023-12-31DKK -1.80-38.9%
20242024-12-31DKK -2.3630.5%
20252025-12-31DKK 13.64N/A
Zealand Pharma A/s sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-100.9%
Q42025-12-31-493.3%
Q12026-03-31-4.5%
Q22026-06-301087.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

DKK 4.48B

-50.8%

Gross Profit

DKK 4.46B

-50.9%

Gross Margin

99.76%

N/A

Market Cap

$3.28BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$6.82M

N/A

Employees

481

N/A

Net Income

DKK 3.90B

-48.5%

EBITDA

DKK 3.86B

-52.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

DKK 14.41B

-13.1%

Total Debt

DKK 409.54M

+3.2%

Accounts Receivable

DKK 3.92B

+2048.9%

Inventory

DKK 0.00

-100.0%

Long Term Debt

DKK 380.64M

+0.3%

Short Term Debt

DKK 28.90M

+42.7%

Return on Assets

13.86%

N/A

Return on Invested Capital

12.74%

N/A

Free Cash Flow

DKK 391.60M

-95.4%

Operating Cash Flow

DKK 404.56M

-95.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CAMRFCamurus AB
$61.75+0.00%
HKMPYHikma Pharmaceuticals PLC
$43.18-0.67%
HKMPFHikma Pharmaceuticals PLC
$22.19+0.00%
AKBLFALK-Abelló A/S
$37.92+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$10.38+0.11%
NVDANvidia
$228.45+0.02%
SPCXSpace Exploration Technologies
$149.74+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$11.01+0.06%

Questions About ZLDPF

What is the current price of Zealand Pharma A/s?

Zealand Pharma A/s is trading at $47.64 per share.

What is the 52-week range for Zealand Pharma A/s?

Over the past 52 weeks, Zealand Pharma A/s has traded between $35.93 and $83.12.

How much debt does Zealand Pharma A/s have?

As of the most recent reporting period, Zealand Pharma A/s reported total debt of DKK 62.86M.

How much cash does Zealand Pharma A/s have on hand?

Zealand Pharma A/s reported DKK 617.62M in cash and cash equivalents in its most recent financial results.

What is Zealand Pharma A/s’s dividend yield?

Zealand Pharma A/s does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services